Biogen makes $5.6B bet on Apellis Pharma

Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion. The deal immediately adds sales revenue and bolsters Biogen's immunology and rare-disease portfolios, strengthening its growth and product mix. Expect a positive near-term reaction for Biogen shares and a meaningful strategic boost to its pipeline, subject to integration and execution risk.

Analysis

Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion. The deal immediately adds sales revenue and bolsters Biogen's immunology and rare-disease portfolios, strengthening its growth and product mix. Expect a positive near-term reaction for Biogen shares and a meaningful strategic boost to its pipeline, subject to integration and execution risk.